CHECK-D: Controlling Hypertension Through Education and Coaching in Kidney Disease

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT04087798
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
350
10
2
45.9
35
0.8

Study Details

Study Description

Brief Summary

Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Control-EDI
  • Behavioral: Intervention-EDI and health coaching
N/A

Detailed Description

Patients that meet eligibility criteria and are seen in a clinic assigned to the control group will be given a Control-Encounter Decision Intervention (Control-EDI) about kidney disease in general (not tailored to the patient) by their primary care provider. Eligible patients that agree to participate and give consent will complete enrollment, 1, 6, and 12 month follow-up visits.

Eligible patients that are seen in a clinic assigned to the intervention group will be given a personalized Intervention-EDI by their primary care provider. Following this, eligible patients that agree to participate and give consent will complete the enrollment visit, and have a baseline call with a health coach. In addition to the 1, 6, 12 month follow-up visits these patients will also have approximately 4-6 phone calls with the health coach between the baseline visit and 11 months after enrollment.

In both groups the study team will be collecting medical information and assessments regarding their health; blood sample and urine samples at baseline and 12 months; approximately 4-6 phone calls; as well as surveys at various time points.

In order to reduce in-person human subject activity due to the Coronavirus disease 2019 (COVID-19) pandemic, participants in both groups receive an at home blood pressure monitor so that systolic- & diastolic-BP data can be collected at all 4 time points (baseline, 1, 6, 12 months).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Cluster Randomized DesignCluster Randomized Design
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Controlling Hypertension Through Education and Coaching in Kidney Disease
Actual Study Start Date :
Feb 4, 2020
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control

Eligible patients enrolled from the control group clinics will be given a Control-EDI which has information about kidney disease in general (not tailored to the patient) during their clinic visit.

Behavioral: Control-EDI
Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
Other Names:
  • Control-Encounter Decision Intervention
  • Experimental: Intervention

    Eligible patients enrolled from the intervention group clinics will be given an Intervention-EDI which has personalized information about kidney disease. There will be space on this for the provider to type in any goals or key points they want the patient to remember. Additionally, patients in this group will also receive health coaching.

    Behavioral: Intervention-EDI and health coaching
    Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient. Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
    Other Names:
  • Intervention-Encounter Decision Intervention
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Systolic Blood Pressure between baseline and 12 months [Baseline, 12 months]

      Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

    Secondary Outcome Measures

    1. Change in Diastolic Blood Pressure between baseline and 12 months [Baseline, 12 months]

      Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.

    2. Slope of systolic BP between baseline and 12 months using all available BP values [Baseline up to 12 months]

      BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

    3. Slope of diastolic BP between baseline and 12 months using all available BP values [Baseline up to 12 months]

      BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.

    4. CKD knowledge measured by the Kidney Knowledge Survey (KiKS) [Baseline up to 12 months]

      This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.

    5. Medication Adherence Self-Efficacy Scale-Revised (MASES-R) [Baseline up to 12 months]

      This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.

    6. Morisky Medication Adherence Scale (MMAS - 8) [Baseline up to 12 months]

      This scale is to quantify adherence to pharmacological treatments by 8 items. Levels of adherence are based on the following scores: <6 = low adherence; 6-<8 = medium adherence; 8 = high adherence.

    7. Visit Time with provider [Enrollment visit (baseline)]

      Length of time provider spends with the patient. This will be compared between the intervention group and control group.

    8. Total time in clinic [Enrollment visit (baseline)]

      Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.

    9. Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ) [Baseline up to 12 months]

      This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.

    10. Satisfaction with CKD care based on Communication Assessment Tool (CAT) [Baseline up to 12 months]

      This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.

    11. Satisfaction with CKD care based on Consultation Care Measure (CCM) [Baseline up to 12 months]

      This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.

    12. Perceptions of health coaching for the intervention group [Baseline up to 12 months]

      During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.

    13. Medication adherence from the electronic medical record (EMR) [Baseline up to 12 months]

      The EMR will be reviewed to evaluate the patients medication refills for adherence.

    14. Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS) [Baseline up to 12 months]

      This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.

    15. Self-reported Blood Pressure-Related Behaviors Survey [Baseline up to 12 months]

      This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.

    16. Provider Adoption based on EMR query and patient survey [Baseline]

      Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.

    17. Provider Fidelity measured by EMR query [Baseline]

      Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.

    18. Provider Perception of Usefulness by provider survey [Baseline up to 12 months]

      Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.

    19. Change in serum creatinine [Baseline, 12 months]

      Change in Serum Creatinine between baseline and 12-months

    20. Change in urine protein-creatinine ratio [Baseline, 12 months]

    21. Change in estimated glomerular filtration rate (eGFR) [Baseline, 12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosis of CKD stage 3, 4, or 5 documented in medical record

    • Aware of CKD diagnosis

    • Has diagnosis of hypertension documented in medical record and most recent Blood Pressure (BP) within the last year meets criteria of uncontrolled hypertension (≥140 mmHg, and/or a diastolic blood pressure ≥90 mmHg noted in an ambulatory care setting within the past one year)

    • Estimated glomerular filtration rate (eGFR) of <60 within the last 18 months documented in the medical record

    Exclusion Criteria:
    • Currently on dialysis permanently (i.e. are considered "end-stage renal disease" and receiving dialysis)

    • Previous kidney transplant

    • Pregnant (indicated by medical record or if patient self-identifies as pregnant)

    • Has cognitive, language, or vision impairment(s) that would prohibit participating in education, taking surveys, or participating in coaching activities

    • Has terminal illness

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Michigan / Domino's Farms Ann Arbor Michigan United States 48105
    2 University of Michigan / Briarwood Family Medicine Ann Arbor Michigan United States 48108
    3 University of Michigan / Brighton Health Center Brighton Michigan United States 48116
    4 University of Michigan / Chelsea Health Center Chelsea Michigan United States 48118
    5 University Health Center - GMAP/Gen Med Detroit Michigan United States 48201
    6 University Health Center - Med Peds Detroit Michigan United States 48201
    7 University of Michigan / Dexter Health Center Dexter Michigan United States 48130
    8 University of Michigan / Livonia Health Center Livonia Michigan United States 48152
    9 University of Michigan / Northville Health Center Northville Michigan United States 48168
    10 University of Michigan / Ypsilanti Health Center Ypsilanti Michigan United States 48198

    Sponsors and Collaborators

    • University of Michigan
    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Investigators

    • Principal Investigator: Julie Wright, MD, University of Michigan

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Julie Wright-Nunes, Assistant Professor Department of Internal Medicine, University of Michigan
    ClinicalTrials.gov Identifier:
    NCT04087798
    Other Study ID Numbers:
    • HUM00136011
    • R01DK115844-01
    First Posted:
    Sep 12, 2019
    Last Update Posted:
    May 31, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 31, 2022